LYEL
Lyell Immunopharma, Inc. NASDAQ Listed Jun 17, 2021$10.93
-0.73%
vs $11.01
Mkt Cap $186.8M
52w Low $10.78
0.5% of range
52w High $38.60
50d MA $13.56
200d MA $19.84
P/E (TTM)
-0.9x
EV/EBITDA
—
P/B
0.8x
Debt/Equity
0.2x
ROE
-110.6%
P/FCF
-1.2x
RSI (14)
17.60
ATR (14)
$0.79
Beta
-0.07
50d MA
$13.56
200d MA
$19.84
Avg Volume
129.2K
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
201 Haskins Way · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -1.90 | -1.92 | -1.1% | 14.21 | -1.5% | +3.5% | -2.6% | +3.8% | -4.8% | -3.0% | — |
| May 6, 2026 | AMC | -2.78 | -1.10 | +60.4% | 20.85 | +1.8% | -3.8% | -3.6% | -0.7% | +0.3% | -0.1% | — |
| Mar 12, 2026 | AMC | -2.15 | -7.68 | -257.2% | 24.78 | +0.0% | -14.2% | -0.6% | -4.7% | -0.4% | +3.5% | — |
| Nov 12, 2025 | AMC | -2.81 | -2.13 | +24.2% | 17.63 | -3.6% | -1.2% | -2.8% | +2.9% | +2.9% | -4.0% | — |
| Aug 12, 2025 | AMC | -3.80 | -2.89 | +23.9% | 10.57 | -12.2% | +2.5% | -0.6% | -1.7% | +2.9% | -0.6% | — |
| May 13, 2025 | AMC | -3.80 | -3.60 | +5.3% | 8.09 | -0.7% | -3.6% | +2.9% | +3.4% | -0.5% | +2.2% | — |
| Mar 11, 2025 | AMC | -0.18 | -0.72 | -300.0% | 13.31 | +2.2% | +0.9% | -9.7% | -3.5% | -11.7% | -6.5% | — |
| Nov 7, 2024 | AMC | -0.20 | -0.17 | +15.0% | 24.40 | +3.3% | +0.0% | -0.8% | -3.3% | -6.0% | +0.0% | — |
| Aug 7, 2024 | AMC | -0.20 | -0.18 | +10.0% | 28.20 | -0.7% | +6.4% | +2.0% | -11.1% | +0.7% | -12.4% | — |
| May 6, 2024 | AMC | -0.20 | -0.24 | -20.0% | 50.80 | -3.1% | +0.0% | -1.6% | +7.2% | -8.2% | -2.4% | — |
| Feb 28, 2024 | AMC | -0.21 | -0.20 | +4.8% | 56.80 | -3.5% | +2.8% | +5.1% | -15.0% | -3.8% | +5.2% | — |
| Nov 7, 2023 | AMC | -0.27 | -0.20 | +25.9% | 45.00 | -0.9% | +4.4% | -6.8% | -24.4% | -6.3% | +22.6% | — |
| Aug 8, 2023 | AMC | -0.30 | -0.26 | +13.3% | 48.00 | +0.0% | -0.4% | -3.3% | +0.0% | -4.8% | +4.1% | — |
| May 4, 2023 | AMC | -0.28 | -0.27 | +3.6% | 48.40 | +5.0% | +2.5% | -7.3% | +7.4% | +5.7% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6 | Stifel | Initiates | Buy | $36 | $13.45 | $14.01 | +4.2% | +5.7% | +3.5% | -2.6% | +3.8% | -4.8% |
| Jul 22 | B. Riley Securities | Initiates | Buy | $44 | $13.11 | $13.68 | +4.3% | -2.1% | -0.5% | -1.2% | +2.6% | +0.2% |
| May 1 | Baird | Initiates | Outperform | $49 | $19.73 | $20.03 | +1.5% | +5.6% | -0.5% | -0.5% | +1.1% | -3.8% |
| Dec 9 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $28.36 | $29.00 | +2.3% | +3.2% | +6.9% | +6.8% | +3.1% | -6.0% |
| Nov 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $19.13 | $19.27 | +0.7% | +18.8% | -0.8% | +8.3% | -1.7% | -7.9% |
| Jun 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.99 | $9.29 | +3.3% | +6.7% | -3.1% | -1.8% | -2.0% | -1.1% |
| Apr 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.18 | $8.79 | -4.2% | -4.4% | -1.3% | +0.9% | +5.1% | +3.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.43 | $13.52 | +0.7% | -9.7% | -3.5% | -11.7% | -6.5% | +20.4% |
| Nov 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.20 | $23.60 | -2.5% | -3.3% | -6.0% | +0.0% | +0.0% | +0.9% |
| Oct 30 | BofA Securities | Downgrade | Buy → Underperform | — | $18.96 | $18.56 | -2.1% | -9.4% | +11.9% | +16.6% | +13.4% | -2.4% |
| Oct 28 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $18.54 | $17.60 | -5.1% | +1.0% | +1.3% | -9.4% | +11.9% | +16.6% |
| Aug 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.40 | $24.20 | -0.8% | +19.7% | -0.7% | +0.7% | -0.7% | +7.6% |
| Jun 27 | BofA Securities | Maintains | Buy → Buy | — | $26.20 | $26.20 | +0.0% | +5.3% | +5.1% | +9.0% | -4.4% | +0.0% |
| Jun 27 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $26.20 | $26.20 | +0.0% | +5.3% | +5.1% | +9.0% | -4.4% | +0.0% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.80 | $49.20 | -3.1% | +0.0% | -1.6% | +7.2% | -8.2% | -2.4% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.80 | $54.80 | -3.5% | +2.8% | +5.1% | -15.0% | -3.8% | +5.2% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.00 | $47.00 | +0.0% | -6.8% | -24.4% | -6.3% | +22.6% | +7.9% |
| Aug 28 | JP Morgan | Downgrade | Overweight → Neutral | — | $45.80 | $44.00 | -3.9% | -3.9% | +5.0% | +1.7% | +1.7% | -2.1% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.00 | $47.40 | -1.2% | -6.2% | -1.3% | -5.0% | -0.9% | -1.4% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $59.60 | $58.80 | -1.3% | +2.0% | +4.9% | +2.8% | +1.8% | -2.1% |
| Nov 14 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $90.60 | $89.60 | -1.1% | +3.8% | -2.1% | -3.3% | -0.9% | -0.5% |
| Nov 11 | Goldman Sachs | Downgrade | Buy → Neutral | — | $99.20 | $95.80 | -3.4% | -8.7% | +3.8% | -2.1% | -3.3% | -0.9% |
| May 24 | Goldman Sachs | Maintains | Buy → Buy | — | $85.60 | $84.40 | -1.4% | -1.9% | -2.1% | -0.5% | +6.1% | -4.6% |
| Mar 31 | Goldman Sachs | Maintains | Buy → Buy | — | $107.20 | $107.80 | +0.6% | -5.8% | +6.1% | +0.0% | -1.3% | -1.7% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $131.60 | $130.40 | -0.9% | -2.0% | -1.1% | +3.8% | +1.8% | -6.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Shook David | Chief Medical Officer | Sell | 500 | $12.70 | $6K | 20,423 | -1.97% | +0.19% |
| Aug 21, 2026 | Seely Lynn | President and CEO | Sell | 9,589 | $15.54 | $149K | 63,899 | -4.45% | +1.43% |
| Aug 21, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 989 | $15.54 | $15K | 16,816 | -4.45% | +1.43% |
| Aug 21, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 1,457 | $15.54 | $23K | 16,220 | -4.45% | +1.43% |
| Aug 10, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 89 | $14.34 | $1K | 17,805 | -4.77% | +16.53% |
| Aug 10, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 131 | $14.34 | $2K | 17,677 | -4.77% | +16.53% |
| Aug 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 621 | $14.34 | $9K | 14,799 | -4.77% | +16.53% |
| Aug 10, 2026 | Seely Lynn | President and CEO | Sell | 390 | $14.34 | $6K | 73,488 | -4.77% | +16.53% |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd | — | Sell | 10 | $13.70 | $137 | 2,857,480 | +1.47% | +2.61% |
| Jun 10, 2026 | Shook David | Chief Medical Officer | Sell | 1,977 | $12.64 | $25K | 20,923 | -1.60% | +1.76% |
| May 11, 2026 | Seely Lynn | President and CEO | Sell | 388 | $18.91 | $7K | 73,878 | -8.19% | +5.51% |
| May 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | 89 | $18.92 | $2K | 17,894 | -8.19% | +5.51% |
| May 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | 130 | $18.92 | $2K | 17,808 | -8.19% | +5.51% |
| May 11, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 217 | $18.91 | $4K | 15,420 | -8.19% | +5.51% |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
LYEL's new executive Lang receives competitive compensation ($560K base plus 40% bonus potential) with full 2026 bonus eligibility, signaling board confidence in his leadership and commitment to retention during critical strategic execution.
Apr 15
8-K
Unknown — 8-K Filing
Lyell's Phase 3 trial of ronde-cel versus competitor CAR-T therapies represents a pivotal commercialization milestone that could validate differentiation and significantly expand addressable market if successful.
Mar 12
8-K
Lyell Immunopharma, Inc. -- 8-K Filing
Lyell Immunopharma appointed a new executive officer with participation in the company's severance plan, potentially affecting shareholder equity structure and executive compensation costs.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Gsk Plc | 1,512,659 | $30M | — | Mar 2026 |
| 2 | Foresite Capital Management Iv, Llc | 800,399 | $16M | — | Mar 2026 |
| 3 | Foresite Capital Management V, Llc | 477,078 | $15M | — | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 786,774 | $11M | Added | Jun 2026 |
| 5 | Orland Properties Ltd | 754,698 | $11M | New | Jun 2026 |
| 6 | Blackrock, Inc. | 724,342 | $10M | New | Jun 2026 |
| 7 | Almitas Capital Llc | 581,407 | $8M | New | Jun 2026 |
| 8 | Susquehanna International Group, Llp | 310,198 | $6M | Added | Mar 2026 |
| 9 | Millennium Management Llc | 367,473 | $5M | Reduced | Jun 2026 |
| 10 | Alphabet Inc. | 293,256 | $4M | — | Jun 2026 |
| 11 | Marshall Wace, Llp | 148,516 | $3M | Added | Mar 2026 |
| 12 | Morgan Stanley | 85,898 | $3M | Added | Dec 2025 |
| 13 | Renaissance Technologies Llc | 130,190 | $2M | Added | Jun 2026 |
| 14 | Rbf Capital, Llc | 88,188 | $2M | Reduced | Mar 2026 |
| 15 | Velan Capital Investment Management Lp | 105,000 | $1M | Added | Jun 2026 |
| 16 | Vanguard Portfolio Management Llc | 91,891 | $1M | Added | Jun 2026 |
| 17 | Mic Capital Management Uk Llp | 87,028 | $1M | — | Jun 2026 |
| 18 | Qube Research & Technologies Ltd | 55,110 | $1M | Added | Mar 2026 |
| 19 | Clearstead Advisors, Llc | 39,916 | $801K | New | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 52,927 | $744K | Added | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$186.8M
Enterprise Value
-$60.4M
P/E (TTM)
-0.93x
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.75x
P/S
6919.50x
P/FCF
-1.24x
EV/EBITDA
—
Shares Out
17.1M
Financials (TTM)
Revenue
$27K
Net Income
-$248.5M
EBITDA
-$239.0M
Free Cash Flow
-$150.8M
Op Cash Flow
-$150.0M
EPS Basic
$-16.06
EPS Diluted
$-11.77
EPS Forward
$-9.46
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$340.1M
Total Liab.
$91.8M
Total Equity
$248.2M
Cash
$247.2M
LT Debt
$0
Book Value/Sh
$14.52
Debt/Equity
0.17x
Current Ratio
5.28
Quick Ratio
5.28
Returns & Growth
ROE
-110.6%
ROA
-80.7%
ROIC
-70.1%
Rev Growth YoY
-41.0%
EPS Growth YoY
-1125.9%
Price Returns
2W
-23.1%
1M
-30.1%
3M
-8.0%
6M
-47.0%
12M
-15.9%
Technicals
52W High
$38.60
52W Low
$10.78
50d MA
$13.56
200d MA
$19.84
RSI (14)
17.60
ATR (14)
$0.79
Beta
-0.07
Avg Volume
129K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$46.00
High
$49.00
Low
$44.00
Median
$45.00
Data updated apr 25, 2026 8:16pm
· Source: financialmodelingprep.com